Effects of CYP2D6 and CYP3A5 Genotypes on the Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Korean Schizophrenic Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Rhee-Hun | - |
dc.contributor.author | Jung, Sun-Min | - |
dc.contributor.author | Kim, Kyoung-Ah | - |
dc.contributor.author | Lee, Duk Ki | - |
dc.contributor.author | Cho, Hyun-Kee | - |
dc.contributor.author | Jung, Bong-Joo | - |
dc.contributor.author | Kim, Young-Ku | - |
dc.contributor.author | Kim, Seung-Hyun | - |
dc.contributor.author | Han, Changsu | - |
dc.contributor.author | Lee, Min-Soo | - |
dc.contributor.author | Park, Ji-Young | - |
dc.date.accessioned | 2021-09-08T16:16:04Z | - |
dc.date.available | 2021-09-08T16:16:04Z | - |
dc.date.created | 2021-06-10 | - |
dc.date.issued | 2009-06 | - |
dc.identifier.issn | 0271-0749 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/119846 | - |
dc.description.abstract | This study was conducted to evaluate the effects of the CYP2D6 and CYP3A5 genotypes on the steady-state plasma levels of risperidone (RIS), 9-hydroxyrisperidone (9-OH-RIS), and the active moiety (RIS plus 9-OH-RIS) in Korean schizophrenic patients. Sixty-four Korean schizophrenic patients were enrolled. CYP2D6 and CYP3A5 genotypes were determined, and the plasma levels of RIS and 9-OH-RIS were measured using high-performance liquid chromatography. The dose-normalized plasma concentrations of RIS, 9-OH-RIS, and the active moiety were compared according to the CYP2D6 and CYP3A5 genotypes. Among the patients, 57 were CYP2D6 extensive metabolizers (EMs; CYP2D6*1/*1, *1/*10, and *10/*10) and 7 were CYP2D6 poor metabolizers (PMs; CYP2D6*1/*5 and *10/*5). For the CYP3A5 genotype, 30 patients were CYP3A5*1 expressors (*1/*1 [n = 1] and *1/*3 [n = 29]) and 34 patients were CYP3A5 nonexpressors (*3/*3). The plasma levels of RIS (2.03 ng/mL per milligram for EMs vs 5.57 ng/mL per milligram for PMs, P < 0.001) and 9-OH-R-IS (5.06 ng/mL per milligram for EMs vs 0.22 ng/mL per milligram for PMs, P < 0.001) were significantly different among CYP2D6 genotype groups, but the CYP2D6 EMs (7.09 ng/mL per milligram) and PMs (5.79 ng/mL per milligram) did not show no difference in the levels of the active moiety (P = 0.470). CYP3A5 nonexpressors exhibited higher plasma concentrations of both RIS and 9-OH-RIS than its expressors. In the case of 9-OH-RIS, CYP3A5 nonexpressors exhibited significantly higher concentrations than CYP3A5 expressors (5.42 vs 3.51 ng/mL per milligram, P = 0.022). In addition, concentrations of the active moiety were also significantly different between the CYP3A5 nonexpressors (8.39 ng/mL per milligram) and expressors (5.30 ng/mL per milligram, P = 0.005). In conclusion, both CYP2D6 and CYP3A5 genotypes affected plasma levels of RIS and 9-OH-RIS, whereas the active moiety levels were influenced only by the CYP3A5 genotype but not by the CYP2D6 genotype. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.subject | HEALTHY-SUBJECTS | - |
dc.subject | CYP3A5-ASTERISK-3 GENOTYPE | - |
dc.subject | CLINICAL-RESPONSE | - |
dc.subject | ACTIVE METABOLITE | - |
dc.subject | JAPANESE PATIENTS | - |
dc.subject | PHARMACOKINETICS | - |
dc.subject | PHARMACODYNAMICS | - |
dc.subject | POLYMORPHISM | - |
dc.subject | CARBAMAZEPINE | - |
dc.subject | 9-HYDROXY-RISPERIDONE | - |
dc.title | Effects of CYP2D6 and CYP3A5 Genotypes on the Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Korean Schizophrenic Patients | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Young-Ku | - |
dc.contributor.affiliatedAuthor | Kim, Seung-Hyun | - |
dc.contributor.affiliatedAuthor | Park, Ji-Young | - |
dc.identifier.doi | 10.1097/JCP.0b013e3181a289e0 | - |
dc.identifier.scopusid | 2-s2.0-67649364234 | - |
dc.identifier.wosid | 000266078900013 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, v.29, no.3, pp.272 - 277 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY | - |
dc.citation.title | JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY | - |
dc.citation.volume | 29 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 272 | - |
dc.citation.endPage | 277 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | HEALTHY-SUBJECTS | - |
dc.subject.keywordPlus | CYP3A5-ASTERISK-3 GENOTYPE | - |
dc.subject.keywordPlus | CLINICAL-RESPONSE | - |
dc.subject.keywordPlus | ACTIVE METABOLITE | - |
dc.subject.keywordPlus | JAPANESE PATIENTS | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | PHARMACODYNAMICS | - |
dc.subject.keywordPlus | POLYMORPHISM | - |
dc.subject.keywordPlus | CARBAMAZEPINE | - |
dc.subject.keywordPlus | 9-HYDROXY-RISPERIDONE | - |
dc.subject.keywordAuthor | risperidone | - |
dc.subject.keywordAuthor | cytochrome P450 2D6 (CYP2D6) | - |
dc.subject.keywordAuthor | cytochrome P450 3A5 (CYP3A5) | - |
dc.subject.keywordAuthor | 9-hydroxyrisperidone | - |
dc.subject.keywordAuthor | pharmacogenetics | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.